GreenLight Biosciences Long Term Debt

GreenLight Biosciences posts a long-term debt of $60M as of March 2023. That compares with $24M in the prior-year period — up 151.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, GreenLight Biosciences's long-term debt was $24M. The latest reading is $60M — a 151.5% year-over-year increase (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of GreenLight Biosciences's financial statement story. At $60M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GRNA's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; GreenLight Biosciences's other metric pages and overview cover the third.